Page last updated: 2024-09-04

cyc 202 and Animal Mammary Carcinoma

cyc 202 has been researched along with Animal Mammary Carcinoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Appleyard, MV; Bray, SE; Kernohan, NM; Lane, DP; Levison, DA; Murray, KE; O'Neill, MA; Paulin, FE; Thompson, AM	1

Other Studies

1 other study(ies) available for cyc 202 and Animal Mammary Carcinoma

Article	Year
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. International journal of cancer, 2009, Jan-15, Volume: 124, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Doxorubicin; Drug Synergism; Female; Humans; Mammary Neoplasms, Animal; Mice; Mice, Nude; Neoplasm Transplantation; Protein Kinase Inhibitors; Purines; Roscovitine	2009

Article

Year

Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.

International journal of cancer, 2009, Jan-15, Volume: 124, Issue:2

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Doxorubicin; Drug Synergism; Female; Humans; Mammary Neoplasms, Animal; Mice; Mice, Nude; Neoplasm Transplantation; Protein Kinase Inhibitors; Purines; Roscovitine

2009